

Jana Fassunke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410982/publications.pdf>

Version: 2024-02-01

23
papers

1,098
citations

840776

11
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

2323
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Diagnostics of Lung Cancer in Serous Effusion Samples. <i>Journal of Molecular Pathology</i> , 2022, 3, 78-87.	1.2	2
2	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.	2.0	6
3	Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence. <i>Lung Cancer</i> , 2021, 151, 91-96.	2.0	5
4	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102.	5.4	11
5	Combining biopsy tools improves mutation detection rate in central lung cancer. <i>ERJ Open Research</i> , 2020, 6, 00002-2020.	2.6	0
6	Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. <i>Lung Cancer</i> , 2020, 144, 40-48.	2.0	9
7	Bronchoscopic Brushing from Central Lung Cancer – Next Generation Sequencing Results are Reliable. <i>Lung</i> , 2019, 197, 333-337.	3.3	7
8	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	17
9	K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019, 14, 606-616.	1.1	178
10	Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20682-e20682.	1.6	2
11	EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20577-e20577.	1.6	1
12	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 509-520.	2.8	29
13	Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 801-804.	2.8	64
14	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, 122-127.	1.1	65
15	Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue. <i>International Journal of Molecular Medicine</i> , 2015, 36, 1233-1243.	4.0	12
16	miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. <i>Molecular Oncology</i> , 2015, 9, 1421-1433.	4.6	71
17	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1049-1057.	1.1	85
18	Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases. <i>Experimental and Molecular Pathology</i> , 2015, 99, 682-686.	2.1	12

#	ARTICLE	IF	CITATIONS
19	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. BMC Cancer, 2015, 15, 291.	2.6	7
20	<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung. Clinical Cancer Research, 2015, 21, 907-915.	7.0	155
21	<i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget, 2015, 6, 10577-10585.	1.8	85
22	Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics. PLoS ONE, 2014, 9, e104566.	2.5	46
23	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer, 2014, 14, 13.	2.6	220